Alternative Data for Dynavax Technologies
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 8 | Sign up | Sign up | Sign up |
| Sentiment | 94 | Sign up | Sign up | Sign up |
| Webpage traffic | 16,000 | Sign up | Sign up | Sign up |
| Employee Rating | 76 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 47 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 19,059 | Sign up | Sign up | Sign up |
| X Followers | 797 | Sign up | Sign up | Sign up |
| X Mentions | 8 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $47,000 | Sign up | Sign up | Sign up |
| Business Outlook | 54 | Sign up | Sign up | Sign up |
| Linkedin Employees | 327 | Sign up | Sign up | Sign up |
About Dynavax Technologies
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States.
| Price | $15.63 |
| Target Price | Sign up |
| Volume | 1,840,000 |
| Market Cap | $1.83B |
| Year Range | $9.36 - $15.72 |
| Dividend Yield | 0% |
| PE Ratio | 58.75 |
| Analyst Rating | 100% buy |
| Industry | Drug Manufacturers |
In the news
 |
Dynavax Technologies Corporation (DVAX) Q3 2025 Earnings Call TranscriptNovember 5 - SeekingAlpha |
|
Dynavax Technologies Corporation 2025 Q3 - Results - Earnings Call PresentationNovember 5 - SeekingAlpha |
 |
Dynavax Technologies Trading At Fair ValueOctober 28 - SeekingAlpha |
 |
Brokerages Set Dynavax Technologies Corporation (NASDAQ:DVAX) Target Price at $24.33October 6 - ETF Daily News |
|
GAMMA Investing LLC Sells 4,450 Shares of Dynavax Technologies Corporation $DVAXOctober 6 - ETF Daily News |
|
Dynavax Technologies Corporation $DVAX Shares Bought by Exchange Traded Concepts LLCSeptember 23 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 95M | 14M | 80M | 27M | 32M | 0.210 |
| Q2 '25 | 95M | 14M | 81M | 19M | 25M | 0.140 |
| Q1 '25 | 68M | 14M | 54M | -96M | -94M | -0.009 |
| Q4 '24 | 72M | 13M | 59M | 7.1M | 12M | 0.050 |
| Q3 '24 | 81M | 13M | 68M | 18M | 24M | 0.120 |
Insider Transactions View All
| Novack David F filed to sell 111,451 shares at $15.5. December 29 '25 |
| Myers Scott Dunseth filed to buy 35,004 shares at $10.8. August 25 '25 |
| KROIN DAVID filed to sell 15,726,349 shares at $10.6. August 22 '25 |
| KROIN DAVID filed to sell 16,696,492 shares at $11. August 22 '25 |
| Novack David F filed to sell 8,078 shares at $14. March 26 '25 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$218.66 0.4% | 44 |
 |
Eli Lilly and CompanyLLY |
$1038.4 0.5% | 64 |
 |
PfizerPFE |
$25.65 0.9% | 50 |
 |
AstrazenecaAZN |
$94.43 0.5% | 48 |
 |
AbbVieABBV |
$214.35 1.1% | 51 |
Read more about Dynavax Technologies (DVAX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
FAQ - Dynavax Technologies
The Market Cap of Dynavax Technologies is $1.83B.
As of today, Dynavax Technologies' PE (Price to Earnings) ratio is 58.75.
Currently, the price of one share of Dynavax Technologies stock is $15.63.
The DVAX stock price chart above provides a comprehensive visual representation of Dynavax Technologies' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Dynavax Technologies shares. Our platform offers an up-to-date DVAX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Dynavax Technologies (DVAX) does not offer dividends to its shareholders. Investors interested in Dynavax Technologies should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Dynavax Technologies are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
